Impact of Erenumab on Comorbid Depression, Anxiety, and Sleep Quality in Migraine: A Registry for Migraine (REFORM) Study.

ABSTRACT:

Background

Migraine frequently co-exists with psychiatric comorbidities, including anxiety, depression, and sleep disturbances. Erenumab, a monoclonal antibody targeting the calcitonin gene-related peptide receptor, effectively reduces migraine frequency, but its impact on psychiatric symptoms remains unclear. This study evaluated the effects of erenumab on anxiety, depression, and sleep quality in individuals with migraine.

Methods

This non-randomized, single-arm, open-label trial was conducted within the prospective Registry for Migraine (REFORM). Adults with migraine received 140-mg erenumab monthly for 24 weeks. Anxiety, depression, and sleep-related symptoms were evaluated at baseline, Week 12, and Week 24 using the hospital anxiety and depression scale (HADS) and the P

SUBMITTER: Raffaelli B 

PROVIDER: S-EPMC12593519 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature